Human Insulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

In the relentless battle against diabetes, the global human insulin market is poised for significant growth. With an estimated value of US$ 45 billion in 2024, this vital sector is projected to soar to US$ 75 billion by 2031, boasting a robust compound annual growth rate (CAGR) of 8%. The prevalence of diabetes, particularly in North America, the Asia-Pacific, Europe, and LATAM regions, underscores the urgent need for advanced insulin solutions.

According to the Centers for Disease Control and Prevention (CDC), over 30 million individuals in the US grapple with diabetes, with a staggering 23 million diagnosed cases. Internationally, the International Diabetes Federation reports that more than 400 million people worldwide suffer from this condition. Notably, while diabetes type 1 is prevalent in North America and the Asia-Pacific, Europe and LATAM are confronted with diabetes type 2. Alarmingly, sedentary lifestyles have expanded the demographic of diabetic patients, including younger individuals, contributing to the burgeoning demand for effective insulin treatments.

Factors Restraining Market Growth

Despite the promising trajectory, the human insulin market faces formidable challenges. Uneven pricing and limited access in emerging economies hinder market expansion, compounded by stringent regulatory hurdles for drug approvals. Delays in the approval process disrupt the demand-supply equilibrium, posing further constraints to market growth.

Dominance of Modern Human Insulin

"Modernization to hold the flag high"

Modern human insulin commands over 80% of the market share, underpinned by relentless research endeavors driving innovation in treatment modalities. Insulin analogues, biosimilars, and human insulin biologics, administered through various delivery devices such as pens, pen needles, and syringes, constitute the cornerstone of modern insulin therapies. Despite the enduring relevance of traditional human insulin, the escalating global diabetic population underscores the indispensability of modern insulin to meet growing demands.

Impact of Covid-19

"End-customers turning out to be more cautious"

The Covid-19 pandemic has precipitated seismic shifts in healthcare dynamics, compelling individuals with chronic conditions like diabetes to adopt heightened vigilance. With diabetes patients at increased risk of Covid-19 complications, a dual focus on disease management and pandemic mitigation strategies has emerged. Consequently, the pursuit of stronger measures to control diabetes serves as a preemptive defense against Covid-19, driving market demand for innovative insulin solutions.

Competitive Landscape and Key Players

Innovation remains the cornerstone of competitiveness in the human insulin market, with key players such as Novo Nordisk A/S, Eli Lilly and Company, Sanofi, and Biocon spearheading advancements in modern insulin therapies. As modern human insulin continues to dominate the market, the competitive landscape is characterized by a relentless pursuit of innovation to address evolving healthcare needs.

Key Companies Profiled in the market include:

• Novo Nordisk A/S.
• Eli Lilly and Company.
• Sanofi.
• Biocon.
• Tonghua Dongbao Pharmaceutical Co., Ltd.
• Adocia, Merck & Co., Inc.
• Pfizer, Inc.
• Wockhardt.
• Julphar.
• Bristol-Myers Squibb Company.
• GlaxoSmithKline Plc.
• Oramed Pharmaceuticals, Inc.

Key Segments Covered in Human Insulin Market

Human Insulin Market by Type

• Modern Human Insulin
• Fast-acting
• Long-acting
• Premix
• Traditional Human Insulin
• Long-acting
• Short-acting
• Fast-acting
• Premix

Human Insulin Market by Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Human Insulin Market by Type of Diabetes

• Diabetes Type 1
• Diabetes Type 2

Human Insulin by Region

• North America Human Insulin Market
• Latin America Human Insulin Market
• Europe Human Insulin Market
• Asia-Pacific Human Insulin Market
• Middle East & Africa (MEA) Human Insulin Market

This product will be delivered within 1-3 business days.